Ambulero will file an IND for our lead gene therapy product AMB-101 by early 2022.
INVESTORS AND DEVELOPMENT
Initial start-up funding and business support has been provided by Ventac Holding, LLC. Drs. Omaida Velazquez’s and Zhao-Jun Liu's research has been supported by the NIH including funding from the prestigious Vascular Interventions/Innovations and Therapeutic Advances (VITA) program. Dr. Velazquez’ work has also been supported by the The Wallace H. Coulter Center for Translational Research at the University of Miami.